Faria Ahmed

Ms. Faria Ahmed

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2019 in Cells
Verified
Journal Article
Open access
PDF file
FAFaria Ahmed
Faria Ahmed
AIAndrea Ibrahim
Andrea Ibrahim
CCCurtis Cooper
Curtis Cooper
AKAshok Kumar
Ashok Kumar
ACAngela M Crawley
Angela M Crawley
Chronic hepatitis C virus (HCV) infection causes generalized CD8+ T cell impairment, not limited to HCV-specific CD8+ T-cells. Liver-infiltrating monocyte-derived macrophages (MDMs) contribute to the local micro-environment and can interact with and influence cells routinely trafficking through the liver, including CD8+ T-cells. MDMs can be polarized into M1 (classically activated) and M2a, M2b, and M2c (alternatively activated) phenotypes that perform pro- and anti-inflammatory functions, respectively. The impact of chronic HCV infection on MDM subset functions is not known. Our results show that M1 cells generated from chronic HCV patients acquire M2 characteristics, such as increased CD86 expression and IL-10 secretion, compared to uninfected controls. In contrast, M2 subsets from HCV-infected individuals acquired M1-like features by secreting more IL-12 and IFN-γ. The severity of liver disease was also associated with altered macrophage subset differentiation. In co-cultures with autologous CD8+ T-cells from controls, M1 macrophages alone significantly increased CD8+ T cell IFN-γ expression in a cytokine-independent and cell-contact-dependent manner. However, M1 macrophages from HCV-infected individuals significantly decreased IFN-γ expression in CD8+ T-cells. Therefore, altered M1 macrophage differentiation in chronic HCV infection may contribute to observed CD8+ T-cell dysfunction. Understanding the immunological perturbations in chronic HCV infection will lead to the identification of therapeutic targets to restore immune function in HCV+ individuals, and aid in the mitigation of associated negative clinical outcomes.

25 June 2024 in American Journal of Gastroenterology
Verified
Journal Article
Open access
SMSanjay K. Murthy
Sanjay K. Murthy
PTParul Tandon
Parul Tandon
PMPriscilla Matthews
Priscilla Matthews
FAFaria Ahmed
Faria Ahmed
MPMichael Pugliese
Michael Pugliese
O(on behalf of the Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC)
on behalf of the Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC)
INTRODUCTION: To study digestive system cancer risks in individuals with inflammatory bowel diseases (IBDs) in the biologic era. METHODS: We used population-level administrative and cancer registry data from Ontario, Canada, (1994–2020) to compare people with IBD to matched controls (1:10 by sex and birth year) on trends in age-sex standardized cancer incidence and risk ratios of incident cancers and cancer-related deaths. RESULTS: Among 110,919 people with IBD and 1,109,190 controls, colorectal cancer incidence (per 100,000 person-years) declined similarly in people with ulcerative colitis (average annual percentage change [AAPC] −1.81; 95% confidence interval [CI] −2.48 to −1.156) and controls (AAPC −2.79; 95% CI −3.44 to −2.14), while small bowel cancer incidence rose faster in those with Crohn's disease (AAPC 9.68; 95% CI 2.51–17.3) than controls (AAPC 3.64; 95% CI 1.52–5.80). Extraintestinal digestive cancer incidence rose faster in people with IBD (AAPC 3.27; 95% CI 1.83–4.73) than controls (AAPC −1.87; 95% CI −2.33 to −1.42), particularly for liver (IBD AAPC 8.48; 95% CI 4.11–13.1) and bile duct (IBD AAPC 7.22; 95% CI 3.74–10.8) cancers. Beyond 2010, the incidences (and respective mortality rates) of colorectal (1.60; 95% CI 1.46–1.75), small bowel (4.10; 95% CI 3.37–4.99), bile duct (2.33; 95% CI 1.96–2.77), and pancreatic (1.19; 95% CI 1.00–1.40) cancers were higher in people with IBD. DISCUSSION: Cancer incidence is declining for colorectal cancer and rising for other digestive cancers in people with IBD. Incidence and mortality remain higher in people with IBD than controls for colorectal, small bowel, bile duct, and pancreatic cancers.